We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel.
- Authors
Jian-Ri Li; Shian-Shiang Wang; Cheng-Kuang Yang; Chuan-Su Chen; Hao-Chung Ho; Kun-Yuan Chiu; Chi-Feng Hung; Chen-Li Cheng; Chi-Rei Yang; Cheng-Che Chen; Shu-Chi Wang; Chia-Yen Lin; Yen-Chuan Ou
- Abstract
Introduction: We performed a chart review study in our castration-resistant prostate cancer (CRPC) patients who received Abiraterone acetate (AA) treatment after docetaxel and identified clinical markers which can predict treatment outcome. Materials and Methods: From 2012 to 2016, 64 patients who received docetaxel after CRPC followed by AA treatment were included. Clinical parameters were recorded and analysis was performed to identify associations between pre-treatment variables and treatment outcome. Results: Thirty three patients (51.6%) achieved a decrease in PSA of 50%. The median PSA progression-free survival and overall survival in the total cohort of 64 patients were 6.6 and 24 months, respectively. Adverse events (AEs) in all grades developed in 35.9% (23/64) patients and mostly were grade 1 or 2. The most common AEs were gastric upset, hypokalemia and elevated liver function tests. Of the eight variables analyzed, first line androgen deprivation therapy (ADT) duration showed positive association to progression free survival (HR 0.98, 95% CI [0.96-0.99], p D 0.012) and overall survival (HR 0.97, 95% CI [0.94-0.99], p D 0.019). Pre-AA PSA and PSA progression ratio showed negative association only to progression free survival (HR 1.0, 95% CI [1.000-1.002], p D 0.025, HR 1.01, 95% CI [1.00-1.01], p < 0.001, respectively). Conclusion: First line ADT duration was positively associated with AA treatment efficacy in progression free survival and overall survival. It can be used as a pre-treatment predictor.
- Subjects
ANDROGEN drugs; ABIRATERONE acetate; PROSTATE cancer treatment; THERAPEUTICS
- Publication
Frontiers in Pharmacology, 2017, Vol 8, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2017.00055